168 related articles for article (PubMed ID: 35641844)
1. Updates in IDH-Wildtype Glioblastoma.
Melhem JM; Detsky J; Lim-Fat MJ; Perry JR
Neurotherapeutics; 2022 Oct; 19(6):1705-1723. PubMed ID: 35641844
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
3. Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Sim HW; Lorrey S; Khasraw M
Curr Neurol Neurosci Rep; 2023 Jun; 23(6):263-276. PubMed ID: 37154886
[TBL] [Abstract][Full Text] [Related]
4. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA
Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Szopa W; Burley TA; Kramer-Marek G; Kaspera W
Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C; Felsberg J; Gramatzki D; Le Rhun E; Clarke J; Soffietti R; Wick W; Chinot O; Ducray F; Roth P; McDonald K; Hau P; Hottinger AF; Reijneveld J; Schnell O; Marosi C; Glantz M; Darlix A; Lombardi G; Krex D; Glas M; Reardon DA; van den Bent M; Lefranc F; Herrlinger U; Razis E; Carpentier AF; Phillips S; Rudà R; Wick A; Tabouret E; Meyronet D; Maurage CA; Rushing E; Rapkins R; Bumes E; Hegi M; Weyerbrock A; Aregawi D; Gonzalez-Gomez C; Pellerino A; Klein M; Preusser M; Bendszus M; Golfinopoulos V; von Deimling A; Gorlia T; Wen PY; Reifenberger G; Weller M
Eur J Cancer; 2023 Aug; 189():112913. PubMed ID: 37277265
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
9. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
11. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract][Full Text] [Related]
12. Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study".
Stoyanov GS
J Neurooncol; 2022 May; 157(3):573-574. PubMed ID: 35378641
[No Abstract] [Full Text] [Related]
13. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma.
Galanis E; Wen PY; de Groot JF; Weller M
Hematol Oncol Clin North Am; 2022 Feb; 36(1):113-132. PubMed ID: 34756799
[TBL] [Abstract][Full Text] [Related]
14. The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma.
Brognaro E
Clin Transl Oncol; 2022 Jan; 24(1):13-23. PubMed ID: 34152549
[TBL] [Abstract][Full Text] [Related]
15. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Oh S; Yeom J; Cho HJ; Kim JH; Yoon SJ; Kim H; Sa JK; Ju S; Lee H; Oh MJ; Lee W; Kwon Y; Li H; Choi S; Han JH; Chang JH; Choi E; Kim J; Her NG; Kim SH; Kang SG; Paek E; Nam DH; Lee C; Kim HS
Nat Commun; 2020 Jul; 11(1):3288. PubMed ID: 32620753
[TBL] [Abstract][Full Text] [Related]
16. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
18. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
19. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
